Morgan Stanley Reiterates Overweight on AbbVie, Maintains $182 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Terence Flynn has reiterated an Overweight rating on AbbVie (NYSE:ABBV) and maintained a price target of $182.
July 11, 2023 | 12:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley has reiterated an Overweight rating on AbbVie and maintained a price target of $182.
The Overweight rating from Morgan Stanley indicates a positive outlook for AbbVie. The maintained price target of $182 suggests that the analyst believes the stock has potential for growth. This could lead to increased investor confidence and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100